MedPath

Clinical Trial of Uterine Artery Embolization for Uterine Leiomyoma

Phase 2
Conditions
Leiomyoma
Registration Number
NCT00821275
Lead Sponsor
Sun Yat-sen University
Brief Summary

The efficacy and safety of uterine artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain. The purpose of this trial is to evaluate the uterine volume and tumor size reduction, symptomatic relief, complication, fertility, ovarian function and quality of life with uterine artery embolization for uterine fibroids comparing with standard surgical methods.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
900
Inclusion Criteria
  • Clinical diagnosis of symptomatic uterine leiomyoma
Exclusion Criteria
  • pregnancy
  • iodine agent allergy
  • patient refuse to take part in this trial
  • tumour size is less than 3cm or beyond 10cm
  • with endometriosis
  • with malignant diseases
  • with abnormal coagulation function which can't restore
  • with acute inflammatory diseases or acute episode of chronic inflammatory diseases
  • with severe heart, lung, liver and kidney, et al. organ diseases.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
quality of life1,3,5,10 year.
pregnant3 years
Secondary Outcome Measures
NameTimeMethod
symptom relief3,6,12,24 months
tumor recurrence1,3,5,10 years
complications3,6,12,24 months
ovarian functions3,6,12 months, 2,3,5 and 10 years
tumour volume3,6,12 18 24 months and 3,5,10 years

Trial Locations

Locations (4)

Nanfang Hospital of Nanfang medical University

🇨🇳

Guangzhou, Guangdong, China

Guangdong Provincial People's Hospital

🇨🇳

Guangzhou, Guangdong, China

the first Affiliated Hospital of Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

Nanfang Hospital of Nanfang medical University
🇨🇳Guangzhou, Guangdong, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.